move to main move to category
  1. HOME
  2. Corporate Information & SBI Group
  3. SBI Biotech

SBI Biotech

A Bio-venture Dedicated to Creation of Innovative Drugs through the Convergence of Advanced Technology Targeting Dendritic Cells with RNAi Technology

SBI Biotech

As a global bio-venture, SBI Biotech brings together multiple drug development pipelines through a global network of researchers in Japan, the United States, Israel, China, South Korea, and other countries. The company was originally founded in 2001 as Ginkgo Biomedical Research Institute by Dr. Ken-ichi Arai, a key executive of the DNAX Research Institute in the United States and head of the University of Tokyo's Institute of Medical Science.

Drug development bio-ventures in Japan commonly succeed in developing one drug but are subsequently unable to create seeds for future drug development activities. In 2012, SBI Biotech strengthened its pipelines and R&D capabilities by acquiring Quark Pharmaceuticals, Inc., a California-based bio-venture with a track record of success in the development of nucleic acid drugs, as a wholly owned subsidiary. This complementing structure should ensure a continuing stream of new drug development seeds.

Research into low-molecular drugs is waning amid a shift to biopharmaceuticals. This has led to a significant change in the drug development structures of major pharmaceutical companies, which are shifting from in-house development to an open innovation model. In Europe and North America, bio-ventures have already become an important source of drug development seeds. There is an urgent need for the creation of a similar structure in Japan, and the government has started to implement priority measures. Bio-ventures are expected to play an increasingly important role in the future. In addition to R&D activities centering on nucleic acid and antibodies, SBI Biotech is also determined to increase its contribution to the growth of the Japanese bio market in collaboration with pharmaceutical companies and university hospitals.

Corporate Profile

Company name SBI Biotech Co., Ltd.
Principal business Pharmaceuticals research and development
Representative Takeshi Irie
Location Izumi Garden Tower, 1-6-1 Roppongi, Minato-ku, Tokyo
Date of establishment March 30, 2001
Paid-in capital 100 million yen
Shareholders * SBI Group 87.64%

* Ownership percentage is based on voting rights. SBI Group's shareholding percentage corresponds to a total percentage based on the IFRS criteria for subsidiary companies and subsidiary funds of the Group.

(As of March 31, 2019)

Corporate Information & SBI Group